Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 inhibitor use, according to data presented at the American College of ...

The phase 3b STEP UP trial in more than 1,400 patients compared a 7.2mg weekly subcutaneous injection of semaglutide to the standard 2.6mg weekly dose sold as Wegovy or a matched placebo.

Researchers conducted a post hoc analysis of the PIONEER trials to compare the efficacy of oral semaglutide versus active comparators in improving T2D cardiometabolic outcomes.

Half of the participants took a semaglutide tablet daily and half took a placebo ... this group and the rate of cardiovascular death was 7% lower. There was no significant difference between ...